In men with non-metastatic breast cancer, cardiovascular cumulative incidence overtakes that of breast cancer early after diagnosis in the oldest patients, which support age-aware cardiovascular attention during survivorship but do not establish that intensified cardiovascular surveillance improves outcomes.
Abstract
Male breast cancer is rare and predominantly affects older patients, who face a substantial competing burden of cardiovascular disease. We aimed to characterize age-specific cumulative incidences of breast cancer, cardiovascular, and other-cause mortality and determine when cardiovascular cumulative incidence overtakes that of breast cancer. Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified men diagnosed with non-metastatic invasive breast cancer during 2000-2022. Cause-specific cumulative incidence was estimated using the Aalen-Johansen estimator, with cardiovascular-breast cancer differences at 5 and 10 years as the primary comparison. Factors associated with cardiovascular death were evaluated using cause-specific Cox and complementary Fine-Gray models. Among 6702 men followed for a median of 67 months, 665 cardiovascular deaths occurred. Mortality patterns were strongly age-dependent. In men aged 80 years or older, cardiovascular cumulative incidence exceeded breast cancer cumulative incidence by 4.6 percentage points at 5 years and 14.6 percentage points at 10 years. In men aged 70-79 years, the differences were not significant at either time point, although an exploratory sustained crossover occurred near 13.6 years. After adjustment, age 80 years or older was strongly associated with cardiovascular death compared with age 60-69 years (hazard ratio 8.54, 95% confidence interval 6.89-10.60); regional stage and unmarried status were also associated with higher cardiovascular mortality. In men with non-metastatic breast cancer, cardiovascular cumulative incidence overtakes that of breast cancer early after diagnosis in the oldest patients. These findings support age-aware cardiovascular attention during survivorship but do not establish that intensified cardiovascular surveillance improves outcomes.
Evaluating the occurrence of new-onset CVD in women with breast cancer undergoing chemotherapy and identifying factors associated with increased risk of cardiovascular disease highlights the need for sustained cardiovascular surveillance in breast cancer survivors.
V. Dvorovy, L. Kováčová, M. Selvek et al.· European Heart Journal, Supp...· 0 citations
In a sample of women with Stage I-III breast cancer who received chemotherapy with curative intent, triple negative subtype, smoking history, tumor size, and surgery type were significantly associated with shorter five-year event free survival.
Samantha Kodikara, Alexis C. Wardell, A. Deal et al.· Current Oncology· 0 citations
Breast cancer is the most common cancer among women in the United States, and cardiovascular disease (CVD) is a leading cause of death in this population. Understanding CVD-related death among breast cancer survivors is critical to inform policies. Previous studies calculating CVD-related death rates in this population...
Le Nguyen, Yan Liu, Chanhyun Park· Public health reports (1974)· 0 citations
BACKGROUND
Breast cancer is the most common malignancy among U.S. women, and survivors face increased risk for subsequent malignancies, including lung cancer. Prior studies have reported associations between breast cancer treatments and lung cancer, but contemporary data remain limited. This study evaluates lung cancer...
Andrea M. Gochi, Tanran Wang, Hyunjee V. Kwak et al.· Annals of Thoracic Surgery· 0 citations
BACKGROUND AND AIMS
The incidence of cancer in people with cardiovascular disease (CVD) is poorly understood. This study aimed to understand the sex differences in incident cancer and cancer-related mortality in people with and without CVD.
METHODS
Participants were drawn from the European Prospective Investigation i...
R. Thuemmler, T. Pana, M. Mamas et al.· European Heart Journal· 0 citations
Background Prediction models can guide breast cancer treatment decisions by estimating individualized prognosis and treatment benefit. Since older women with breast cancer are more heterogeneous and face more competing non–breast cancer mortality, model performance may differ from that observed in the general breast ca...
J. Wolbink, L. van Bodegom-Vos, Luuk C. A. Ciere et al.· Breast· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.